Syndax Pharmaceuticals Inc (SNDX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Syndax Pharmaceuticals Inc reported revenue of $172.35M, up 627.8% from the prior year. The company ran a net loss, with a net margin of -165.6%. It held $529.71M in total assets against $465.08M in total liabilities.
Key ratios (FY2025)
-158.4%
Operating margin
-165.6%
Net margin
-441.6%
Return on equity
+627.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172.35M | $23.68M | $0 | $0 | $139.71M | $1.52M | $1.52M | $1.52M | $2.11M | $1.22M |
| Operating Income | -$273.08M | -$339.67M | -$229.95M | -$151.76M | $26.22M | -$71.42M | -$57.54M | -$75.88M | -$61.95M | -$43.77M |
| Net Income | -$285.42M | -$318.76M | -$209.36M | -$149.34M | $24.93M | -$73.16M | -$56.05M | -$73.96M | -$60.80M | -$44.47M |
| EPS (Diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 | $-1.87 | $-1.84 | — | — | — |
| Total Assets | $529.71M | $724.82M | $612.88M | $497.24M | $449.66M | $300.61M | $63.52M | $83.94M | $137.19M | $109.01M |
| Total Liabilities | $465.08M | $436.69M | $58.68M | $29.79M | $41.29M | $48.42M | $31.93M | $30.89M | $32.87M | $24.87M |
| Shareholders' Equity | $64.63M | $288.12M | $554.20M | $467.45M | $408.37M | $252.19M | $31.60M | $53.05M | $104.32M | $84.14M |
| Cash & Equivalents | $134.93M | $154.08M | $295.39M | $74.36M | $221.97M | $115.24M | $24.61M | $33.77M | $35.17M | $23.84M |
| Operating Cash Flow | -$322.98M | -$274.90M | -$160.60M | -$133.68M | $29.13M | -$71.26M | -$50.61M | -$68.53M | -$47.37M | -$35.16M |
| Capital Expenditures | $187.0K | $0 | $0 | $0 | $129.0K | $0 | — | $187.0K | $84.0K | $261.0K |
| Shares Outstanding | 87.41M | 85.69M | 84.83M | 68.11M | 54.98M | 47.88M | 27.14M | 24.84M | 24.39M | 18.22M |